This report was first published by Endpoints News. To see the original version, click here
One of the most closely watched obesity assets in the clinic, Lilly’s triple-G agonist retatrutide, caused patients with obesity and knee osteoarthritis to lose an average of 23.7% of their body weight at around 16 months in a late-stage trial.
The weight loss with the shot is the most profound ever seen in a clinical trial at this extended time period. Retatrutide could turn out to be the most powerful obesity drug yet, and if it gets to market, it will allow Lilly to extend its already impressive lead over its one-time rival Novo Nordisk.
您已閱讀15%（635字），剩余85%（3718字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。